Biomarkers via Advanced IHC & Spatial Imaging
Biomarkers via Advanced IHC & Spatial Imaging
Understanding the localized impact of a therapeutic requires preserving the complex architecture of intact tissue. By integrating highly multiplexed Immunohistochemistry (IHC) with advanced spatial imaging, we provide a continuous analytical thread from early drug discovery in animal models to definitive biomarker evaluation in human clinical trials.
This high-dimensional spatial data accelerates decision-making across the entire translational pipeline:
Biodistribution & Target Engagement:
Visually map exactly where targeted biologics, advanced cell therapies, or ternary polyplex formulations localize within animal tissues. This confirms target engagement at the single-cell level and strictly validates the mechanism of action (MoA) in vivo.
Preclinical Spatial Toxicology:
Detect localized, tissue-specific toxicity or off-target binding early in development. By identifying exactly which cell populations are adversely affected in preclinical models, teams can confidently de-risk candidates before IND submission.
Microenvironment Characterization:
In complex disease models such as syngeneic tumor models or induced autoimmune tissues, spatial profiling quantifies immune cell infiltration, cell-to-cell interactions, and the reorganization of the structural stroma in response to treatment.
